Randomised clinical trial: alosetron improves quality of life and reduces restriction of daily activities in women with severe diarrhoea-predominant IBS.

ABSTRACT:

Background

Patients with irritable bowel syndrome with diarrhoea (IBS-D) experience restriction in daily activities and decreased health-related quality of life (QOL).

Aim

To investigate effects of alosetron on patient-reported health-related QOL, satisfaction and productivity in women with severe IBS-D.

Methods

A total of 705 women (severe IBS-D, Rome II criteria) randomised to alosetron 0.5 mg QD, 1 mg QD, 1 mg BID, or placebo for 12 weeks were studied. IBSQOL, treatment satisfaction, daily activities, and lost workplace productivity (LWP) were evaluated at randomisation and Week 12.

Results

One or more doses of alosetron significantly improved all IBSQOL domains except for sexual function from baseline vs. placebo. The magnitude of IBSQOL changes was consist

SUBMITTER: Cremonini F 

PROVIDER: S-EPMC3464357 | biostudies-literature | 2012 Sep

REPOSITORIES: biostudies-literature